Clinical Edge Journal Scan

Pseudoceramide+steroid cream rapidly improved skin barrier function in atopic dermatitis


 

Key clinical point: A 2-week treatment with a test cream (TC) containing a steroid and pseudoceramide rapidly improved skin barrier function compared with a control cream (CC) containing only steroids in patients with mild-to-moderate atopic dermatitis (AD).

Major finding: In the TC group, the mean skin hydration value (48.0; P < .01) and transepidermal water loss (−2.1; P < .05) improved significantly as early as at 1 week after application, with similar improvements observed at 2 weeks; however, no significant improvements were observed in the CC group.

Study details: Findings are from a parallel, double-blind study including 36 patients with mild-to-moderate AD skin symptoms on the inner forearm who were randomly assigned to receive a TC containing 0.15% prednisolone valerate acetate (PVA)+3% synthetic pseudoceramide or a CC containing 0.15% PVA for 2 weeks.

Disclosures: This study was fully funded by Kao Corporation, Japan. The authors declared no conflicts of interest.

Source: Okoshi K et al. Efficacy of pseudo-ceramide-containing steroid lamellar cream in patients with mild to moderate atopic dermatitis: A randomized, double-blind study. Dermatol Ther (Heidelb). 2022;12:1823–1834 (Jul 19). Doi: 10.1007/s13555-022-00766-2

Recommended Reading

Topical ruxolitinib quickly relieves atopic dermatitis itch in Black patients
MDedge Dermatology
Commentary: Conditions Associated with AD, August 2022
MDedge Dermatology
Vitamin D supplements during pregnancy may protect infants from atopic eczema
MDedge Dermatology
Intralesional Human Papillomavirus Vaccine Therapy for Recalcitrant Plantar Wart Triggers Gout Flare
MDedge Dermatology
Abrocitinib more promising than dupilumab in moderate-to-severe atopic dermatitis
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Long-term safety and effectiveness of tralokinumab
MDedge Dermatology
Patients with controlled atopic dermatitis can opt for dupilumab dose reduction
MDedge Dermatology
Progressive and sustained improvement in atopic dermatitis with tralokinumab plus TCS as needed
MDedge Dermatology
Dupilumab effective against pruritus in atopic dermatitis in real-life settings
MDedge Dermatology
Dupilumab effective and safe in special populations
MDedge Dermatology